generation run 2026-05-09
78 min completedmodel pipeline-v5plan not recordedrun/786800ac…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- taper_protocol_source
- equivalence_ratio_unverified
- inpatient_taper_gap
Reproduce
- inputs
- 36 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | flunitrazepam dependence withdrawal tolerance abuse | 10 | 2 | Papers with direct relevance to flunitrazepam tolerance and dependence mechanisms |
| 2 | PubMed | flunitrazepam Rohypnol drug-facilitated sexual assault date rape | 10 | 5 | Papers on DFSA directly relevant to harm reduction and forensic sections |
| 3 | PubChem | flunitrazepam | 1 | 1 | Only result, confirmed chemical identity data matching brief |
| 4 | PubMed | flunitrazepam pharmacology mechanism GABA receptor | 10 | 1 | PMID 34396551 directly reviews flunitrazepam pharmacology and GABA-A receptor mechanism |
| 5 | OpenAlex | flunitrazepam pharmacology receptor binding | 10 | — | None selected — all papers used flunitrazepam as radioligand tool, not study subject |
| 6 | PubMed | flunitrazepam pharmacokinetics humans bioavailability metabolism | 8 | 4 | Selected papers specifically studying flunitrazepam PK/bioavailability and metabolism reviews |
| 7 | WebSearch | flunitrazepam legal status UK Australia Canada Europe scheduling | 10 | 3 | International legal status data |
| 8 | Britannica | flunitrazepam history pharmacology | 1 | 1 | Historical context not available in peer-reviewed literature |
| 9 | WebSearch/DEA | flunitrazepam legal status DEA Schedule IV United States Drug Induced Rape Prevention Act 1996 | 10 | 2 | Legal status data not available in PubMed |
| 10 | ClinicalTrials.gov | flunitrazepam | 2 | 2 | Both trials relevant to flunitrazepam clinical context |
| 11 | PubMed | flunitrazepam amnesia anterograde memory impairment | 10 | 7 | Primary sources for anterograde amnesia effects and forensic implications |
| 12 | PubMed | flunitrazepam overdose toxicity case report fatal | 2 | 2 | Direct case reports of fatal flunitrazepam toxicity |
| 13 | PubMed | flunitrazepam urine detection forensic toxicology metabolites | 8 | 3 | Directly relevant to metabolism, forensic detection, and metabolic pathways |
| 14 | PubMed | PMID 6114680 - clinical PK midazolam flunitrazepam diazepam | 1 | 1 | Core PK parameters |
| 15 | PubMed | flunitrazepam subjective effects human controlled study | 8 | 6 | Direct human data on subjective effects, dose-response, route of administration, and abuse liability |
| 16 | PubMed | PMID 2096104 - flunitrazepam pharmacokinetics liver disease | 1 | 1 | Definitive human PK study |
| 17 | PubMed | flunitrazepam CYP3A4 CYP2C19 metabolism | 3 | 4 | Definitive CYP metabolism characterization |
| 18 | WebSearch | flunitrazepam SMILES CAS DrugBank pharmacokinetics | 10 | 2 | Chemical identity and PK consolidation |
| 19 | PubMed | buprenorphine flunitrazepam opioid interaction | 2 | 3 | Critical drug interaction data for harm reduction section |
| 20 | ChemicalBook | flunitrazepam physical properties melting point pKa | 1 | 2 | Physical property data not available from PubChem API call |
| 21 | PubMed + WebSearch | Final data extraction: CYP enzymes, PK, legal status, forensic detection | 15 | 1 | Final data consolidation for research output |
| 22 | WebSearch | flunitrazepam reformulation color dye 1997 Roche | 8 | 2 | Historical reformulation data for harm reduction section |
| 23 | Multiple | Cross-referencing seed data dose ranges against published controlled studies | 5 | 3 | Verification of seed data against primary literature |
105 claims by section — every cited sentence, checked against its source
safety34 · 21 ok
Multiple routes of abuse are documented: oral, intranasal, and intravenous.supported
Intranasal flunitrazepam: detectable in blood at 5 min. Abuse liability confirmed. pmid:8081180
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A separate fatal case involving combined flunitrazepam and triazolam overdose confirmed the lethality of benzodiazepine polypharmacy, with blood 7-aminoflunitrazepam reaching 1,270 ng/g.supported
Fatal case: blood 7-aminoflunitrazepam 1,270 ng/g. paf.0b013e31820f1514
Claim in safety — inconclusiveinconclusiveworking →
At therapeutic doses (1–2 mg), flunitrazepam produces reliable memory blackouts for events occurring after drug administrationsupported
2 mg flunitrazepam produced greatest anterograde memory impairment. No retrograde amnesia. pmid:2905806
This amnesia is potentiated by concurrent alcohol use and creates a dual vulnerability: individuals under the influence may engage in dangerous or violent behavior they cannot subsequently recall, and they are simultaneously vulnerable to exploitation by others during amnestic periods.supported
5 forensic psychiatric patients; all committed extremely violent crimes while intoxicated with flunitrazepam ± alcohol/other drugs; anterograde amnesia confirmed in all. pmid:12108561
This amnesia is potentiated by concurrent alcohol use and creates a dual vulnerability: individuals under the influence may engage in dangerous or violent behavior they cannot subsequently recall, and they are simultaneously vulnerable to exploitation by others during amnestic periods.supported
Qualitative study: amnesia especially after short-acting benzodiazepines + alcohol. Users described victimization and violent behavior during amnestic periods. pmid:27644866
The combination with opioids — particularly buprenorphine — has caused multiple documented deaths in France, where both drugs were concurrently prescribedsupported
Deaths reported among heroin addicts from combined buprenorphine and benzodiazepines (including flunitrazepam). pmid:16958555
Forensic case studies document associations between flunitrazepam intoxication (particularly with alcohol co-ingestion) and violent criminal behavior, impulsive decision-making, and profound disinhibition. Delusions of sobriety — the subjective belief of normal functioning despite measurable impairment — are reported in high-dose users and compound the risk of harm during intoxication.supported
5 forensic psychiatric patients; all committed extremely violent crimes while intoxicated with flunitrazepam ± alcohol/other drugs; anterograde amnesia confirmed in all. pmid:12108561
Forensic case studies document associations between flunitrazepam intoxication (particularly with alcohol co-ingestion) and violent criminal behavior, impulsive decision-making, and profound disinhibition. Delusions of sobriety — the subjective belief of normal functioning despite measurable impairment — are reported in high-dose users and compound the risk of harm during intoxication.supported
Case of serial murderer intoxicated with FZ; severe violence and anterograde amnesia. pmid:14550609
Forensic case studies document associations between flunitrazepam intoxication (particularly with alcohol co-ingestion) and violent criminal behavior, impulsive decision-making, and profound disinhibition. Delusions of sobriety — the subjective belief of normal functioning despite measurable impairment — are reported in high-dose users and compound the risk of harm during intoxication.supported
Users described victimization and violent behavior during amnestic periods. pmid:27644866
Qualitative research with high-dose benzodiazepine users reveals that both victimization and perpetration of violence during amnestic episodes are common experiences in this population.supported
Users described victimization and violent behavior during amnestic periods. pmid:27644866
In squirrel monkeys receiving 1 mg/kg flunitrazepam daily for 18 days:supported
1 mg/kg flunitrazepam for 18 days in squirrel monkeys. pmid:7617819
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Flunitrazepam ranks among the highest-abuse-potential benzodiazepines in systematic assessments, scoring highly on reinforcing effects, abuse prevalence, sedation and amnesia severity, and overdose lethalitysupported
Algorithm comparing 19 hypnotics including flunitrazepam. Analysis of reinforcing effects, withdrawal, actual abuse, sedation/memory impairment, overdose lethality. pmid:16336040
Claim in safety — inconclusiveinconclusiveworking →
Multiple routes of abuse are documented: oral, intranasal, and intravenous.supported
multiple ROAs including injection. pmid:10402150
The interaction is purely pharmacodynamic: flunitrazepam does not inhibit buprenorphine metabolism or alter its cerebral distributionsupported
Adverse buprenorphine+flunitrazepam interaction is not caused by inhibition of drug metabolism. pmid:10873929
The interaction is purely pharmacodynamic: flunitrazepam does not inhibit buprenorphine metabolism or alter its cerebral distributionsupported
no pharmacokinetic interaction in plasma or brain; purely pharmacodynamic. pmid:15917146
This combination is not reversed by naloxone due to buprenorphine's high μ-receptor affinity and slow dissociation kinetics.supported
Pharmacodynamic interaction causes respiratory depression not reversed by naloxone. pmid:16958555
Claim in safety — inconclusiveinconclusiveworking →
Drugs that inhibit CYP3A4 — including azole antifungals (ketoconazole, itraconazole), HIV protease inhibitors (ritonavir, lopinavir/r), macrolide antibiotics (erythromycin, clarithromycin), and grapefruit juice (chronic consumption) — are expected to produce clinically significant increases in flunitrazepam plasma concentrations based on in vitro enzyme kinetic datasupported
CYP3A interactions with flunitrazepam are clinically anticipated. pmid:11159802
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
However, re-sedation is expected because flumazenil's half-life (0.7–1.3 hours) is far shorter than flunitrazepam's (22 hours)supported
Flumazenil pharmacokinetics: short half-life 0.7-1.3h vs BZDs. Re-sedation risk. pmid:2842128
Claim in safety — inconclusiveinconclusiveworking →
History of substance use disorder: High abuse liability and reinforcement potential increase relapse risk (relative)supported
Analysis of reinforcing effects, withdrawal, actual abuse. pmid:16336040
Concurrent opioid use: Pharmacodynamic synergism producing respiratory depression not reversed by naloxone (absolute)supported
Pharmacodynamic interaction causes respiratory depression not reversed by naloxone. pmid:16958555
Concurrent ethanol use: Synergistic CNS depression substantially reduces lethal threshold (absolute)supported
Deaths from flunitrazepam alone and flunitrazepam + ethanol combination. pmid:8311057
pharmacology19 · 13 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Flunitrazepam exhibits greater potency and higher affinity for the GABA-A receptor than most benzodiazepines, including diazepam and nitrazepamsupported
Flunitrazepam has greater potency and higher affinity for the type A GABA receptor than most benzodiazepines. jcph.1922
Absorption follows a three-compartment pharmacokinetic model.supported
Three-compartment model pharmacokinetics described. pmid:23801
Claim in pharmacology — inconclusiveinconclusiveworking →
Plasma protein binding is high at approximately 95.8% (free fraction 4.20 ± 0.34%), predominantly to albuminsupported
Free fraction of flunitrazepam 4.20±0.34% (protein binding ~95.8%). pmid:2707926
The volume of distribution at steady state (VdSS) is 80–100 L, with total plasma clearance of approximately 250 mL/min and oral clearance of 3.5 ± 0.8 mL/min/kg.supported
total plasma clearance 250 mL/min, VdSS 80-100L. pmid:6114680
The volume of distribution at steady state (VdSS) is 80–100 L, with total plasma clearance of approximately 250 mL/min and oral clearance of 3.5 ± 0.8 mL/min/kg.supported
Oral clearance 3.5±0.8 mL/min/kg. pmid:2096104
The distribution half-life is approximately 4.5 hours, and the elimination half-life is 22 ± 5 hours in healthy subjects (range across studies: 16–35 hours)supported
Flunitrazepam: biological half-life 4.5h. pmid:6114680
The distribution half-life is approximately 4.5 hours, and the elimination half-life is 22 ± 5 hours in healthy subjects (range across studies: 16–35 hours)partially supported
Apparent elimination half-life 22±25h in healthy subjects. pmid:2096104
Flunitrazepam undergoes oxidative metabolism via two principal cytochrome P450 pathways:supported
CYP2C19 and CYP3A4 are principal CYPs. pmid:11259331
Flunitrazepam undergoes oxidative metabolism via two principal cytochrome P450 pathways:supported
3-Hydroxylation (CYP3A4) accounts for >80% of intrinsic clearance. pmid:11159802
At therapeutic plasma concentrations (approximately 0.03 μM), CYP2C19 accounts for ~63% of N-demethylation and CYP3A4 for ~37%.supported
In vivo: CYP2C19 contributes 63%, CYP3A4 37% to desmethylflunitrazepam formation at therapeutic concentrations. pmid:11259331
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Comprehensive urinary metabolite profiling has identified 25 metabolites in total (13 Phase I, 12 Phase II) via LC-QE-HF-MS, including N-glucuronide and O-glucuronide conjugatessupported
25 metabolites identified (13 phase I, 12 phase II). Eight metabolic pathways including glucuronidation. jms.4383
CYP2C19 poor metabolizers show altered metabolite ratios (reduced desmethylflunitrazepam formation), but an in vivo study demonstrated that this polymorphism does not substantially alter overall clinical effects of flunitrazepamsupported
CYP2C19 activity correlates with flunitrazepam metabolite ratios but does not substantially affect clinical effects. pmid:12640218
Single-dose oral pharmacokinetic parameters did not differ significantly between healthy subjects and patients with hepatitis or cirrhosissupported
Liver disease does not significantly alter pharmacokinetics. pmid:2096104
Claim in pharmacology — inconclusiveinconclusiveworking →
summary10 · 6 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Metabolism proceeds through CYP2C19-mediated N-demethylation (~63% contribution at therapeutic concentrations) and CYP3A4-mediated 3-hydroxylation (>80% of intrinsic clearance for that pathway), yielding the pharmacologically active metabolite desmethylflunitrazepamsupported
In vivo: CYP2C19 contributes 63%, CYP3A4 37% to desmethylflunitrazepam formation at therapeutic concentrations. pmid:11259331
Metabolism proceeds through CYP2C19-mediated N-demethylation (~63% contribution at therapeutic concentrations) and CYP3A4-mediated 3-hydroxylation (>80% of intrinsic clearance for that pathway), yielding the pharmacologically active metabolite desmethylflunitrazepamsupported
3-Hydroxylation (CYP3A4) accounts for >80% of intrinsic clearance. pmid:11159802
The subjective experience is dominated by rapid-onset sedation, potent anterograde amnesia, anxiolysis, muscle relaxation, and dose-dependent disinhibition — with controlled studies demonstrating a distinct euphorigenic window at medium doses (1.25 mg) that is suppressed at higher doses by overwhelming sedation.supported
Flunitrazepam at medium dose (1.25mg fast onset) produces euphorigenic effects; high dose unpleasant sedation. pmid:11672943
Claim in summary — inconclusiveinconclusiveworking →
Physical dependence develops rapidly; flumazenil-precipitated withdrawal produced convulsions in non-human primates after as few as 9 days of daily administrationpartially supported
1 mg/kg flunitrazepam for 18 days in squirrel monkeys. Flumazenil-precipitated withdrawal showed convulsions. pmid:7617819
Among benzodiazepine abusers in opioid maintenance programs, 92.9% selected flunitrazepam as their primary agent — the highest preference of any benzodiazepine studiedsupported
Flunitrazepam most commonly abused BZD (92.9%). pmid:10402150
The combination with opioids, particularly buprenorphine, produces pharmacodynamic respiratory depression not reversible by naloxonesupported
Pharmacodynamic interaction causes respiratory depression not reversed by naloxone. pmid:16958555
pharmacokinetic-detail9 · 6 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Intranasal administration produces detectable venous blood concentrations within 5 minutes, with peak plasma concentrations comparable to oral and intramuscular routes achieved at approximately 110 minutes.supported
Intranasal flunitrazepam: detectable in blood at 5 min, peak comparable to oral/IM at 110 min. pmid:8081180
A total of 25 metabolites have been identified in human urine (13 Phase I, 12 Phase II), including 9 previously unreported Phase II glucuronide conjugatessupported
25 metabolites identified (13 phase I, 12 phase II). Eight metabolic pathways including glucuronidation. jms.4383
Ketoconazole reduces 3-hydroxyflunitrazepam formation to less than 10% of control valuessupported
Ketoconazole reduces 3-OH FNTZ to <10% of control. pmid:11159802
Direct clinical studies confirming the magnitude of these interactions in humans have not been published; the prediction is based on in vitro enzyme kinetic data.supported
CYP3A interactions with flunitrazepam are clinically anticipated. pmid:11159802
CYP3A4 inducers — including rifampin, carbamazepine, and phenytoin — would be expected to decrease flunitrazepam plasma concentrations, though this has not been confirmed clinically.supported
3-Hydroxylation (CYP3A4) accounts for >80% of intrinsic clearance. CYP3A interactions with flunitrazepam are clinically anticipated. pmid:11159802
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
CYP2C19 poor metabolizers exhibit reduced formation of desmethylflunitrazepam but show no clinically significant alteration in overall pharmacological effect or adverse event profilesupported
CYP2C19 activity correlates with flunitrazepam metabolite ratios but does not substantially affect clinical effects. pmid:12640218
neuroscience8 · 1 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Neurophysiological studies using event-related potentials (ERP) and EEG have confirmed that flunitrazepam-induced sedation produces measurable changes in cortical processing speed and amplitude, corroborating subjective sedation reports with objective biomarkers.supported
ERP, EEG, and behavioral measures assessing flunitrazepam-induced sedation states. pmid:12691789
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
clinical-evidence7 · 6 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
In healthy volunteers, flunitrazepam 2 mg produced the most intense disruptive psychomotor effects of any condition tested and significant increases on ARCI "liking," "good effects," and "high" scales, indicating higher abuse liability than typical benzodiazepines.supported
Flunitrazepam 2mg: most intense disruptive effects on performance, increases in 'liking', 'good effects', 'high' scales; higher abuse liability than other benzodiazepines. pmid:8724443
A double-blind, placebo-controlled study in 40 healthy men demonstrated that 2 mg flunitrazepam produced the greatest anterograde memory impairment compared with lormetazepam and placebosupported
40 healthy men, double-blind placebo-controlled. 2 mg flunitrazepam produced greatest anterograde memory impairment. pmid:2905806
Both agents improved sleep parameters; flunitrazepam produced notable anterograde amnesia as a confirmed adverse effect at this dosesupported
No significant difference in sleep efficacy. Flunitrazepam caused anterograde amnesia (night-day test). Zolpidem did not impair memory. pmid:2092963
Three randomized, double-blind, placebo-controlled crossover trials in healthy male volunteers examined dose-response and rate-of-onset effects on abuse potential:supported
Randomized placebo-controlled trials in healthy volunteers. pmid:11672943
Triazolam did not produce this effect at equivalent doses, reinforcing flunitrazepam's distinct abuse liability in opioid-dependent populations.supported
Evidence for higher abuse potential than other benzodiazepines in opioid-dependent population. pmid:9888625
Subjects reported liking the subjective effects.supported
Subjects reported liking drug effects; sedation well-tolerated. pmid:8081180
comparative-pharmacology6 · 4 ok
It exhibits greater GABA-A receptor affinity than diazepam and nitrazepam, with therapeutic doses (1–2 mg) an order of magnitude lower than diazepam's standard anxiolytic dose range (5–20 mg)supported
Flunitrazepam has greater potency and higher affinity for the type A GABA receptor than most benzodiazepines. jcph.1922
Flunitrazepam ranks among the highest-abuse-potential benzodiazepines in systematic comparative analyses, based on reinforcing effects in preclinical and clinical models, documented prevalence of abuse, sedation and amnesia severity, and overdose lethality.supported
Algorithm comparing 19 hypnotics including flunitrazepam. Analysis of reinforcing effects, withdrawal, actual abuse, sedation/memory impairment, overdose lethality. pmid:16336040
In a direct comparative study, flunitrazepam produced significant euphoria (ARCI-MBG increases) in methadone-maintained patients at 4 mg, whereas triazolam did not produce equivalent euphorigenic effects — indicating that the abuse liability difference is not simply a function of dose or half-life.supported
Flunitrazepam 4mg caused euphoria (ARCI-MBG, high VAS). Evidence for higher abuse potential than other benzodiazepines in opioid-dependent population. pmid:9888625
Controlled comparison demonstrated that flunitrazepam 2 mg produced greater anterograde amnesia than lormetazepam at equivalent dosessupported
2 mg flunitrazepam produced greatest anterograde memory impairment. pmid:2905806
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
history5 · 1 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Its prominence in DFSA casework has declined somewhat as gamma-hydroxybutyrate (GHB) and other agents gained notoriety, though flunitrazepam continues to appear in forensic casework globallysupported
Flunitrazepam and GHB infrequently detected in 2019-2023 DFC casework; designer benzodiazepines emerging as new DFSA agents. 1556-4029.70151
receptor-pharmacology3 · 2 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Flunitrazepam demonstrates greater potency than diazepam, nitrazepam, and most other classical benzodiazepines at the GABA-A benzodiazepine sitesupported
Flunitrazepam has greater potency and higher affinity for the type A GABA receptor than most benzodiazepines. jcph.1922
However, flumazenil's short half-life (0.7–1.3 hours) relative to flunitrazepam's long elimination half-life (22 hours) creates a risk of re-sedation after initial reversal — necessitating repeated flumazenil dosing or continuous infusion in clinical management.supported
Flumazenil pharmacokinetics: short half-life 0.7-1.3h vs BZDs. Re-sedation risk. pmid:2842128